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Introduction
 Electrical pulmonary vein isolation (PVI) for atrial fibrillation 
(AF) is an established and effective therapy[1]. Clinical trials have 
demonstrated that an ablation strategy is generally superior to 
antiarrhythmic medications for the treatment of AF[2]. Radiofrequency 
energy is the most common energy source used for ablation and is 
often delivered in a point-by-point fashion around the pulmonary 
veins. The original, non-irrigated catheters, recorded the temperature 
via a thermistor at the tip of the catheter and measured impedance 
changes over the duration of ablation. Later, irrigated catheters were 
introduced for improved ablation efficacy and safety[3]. A limitation 
of irrigated catheters is the inability to measure the temperature at 
the tissue level of ablation due to the intentional cooling effect of the 
irrigant on the catheter’s thermistor. The next major innovation in 
ablation technology, which was approved by the FDA in 2014, was 
the ability to measure catheter-tissue contact force (CF) in real-time 
and to use that information to guide ablation. BiosenseWebseter’s 
Smarttouch catheter was approved on February 25, 2014 and St. Jude 
Medical’s TactiCath was approved on October 27, 2014[4,5]. The use 
of contact force-guided ablation has been demonstrated to reduce 
ablation gaps and improve ablation effectiveness[6,7,8].
Once the CF catheters were approved at our institution we 
adopted them into use for pulmonary vein isolation in place of the 
irrigated, non-CF ablation catheters used previously. As with any 
new technology, there was a requisite period of introduction and 
transition. The purpose of this observational study was to assess 
the impact of the single variable of incorporating CF technology 
on procedural and clinical characteristics at the time of transition 
to this technology. The hypothesis was that the introduction of CF 
technology would improve both procedural and clinical aspects 
of PVI. We expected that cases would take less time, require less 
ablation, have fewer complications, and have better clinical outcomes 
with CF technology. The other aspects of ablation, including the 
ablation strategy, the personnel (a single attending electrophysiologist 
working with one of three fellows depending on the academic year), 
the other recording catheters, and the workflow remained the same.
Methods
 This  retrospective review included the period of time from July 2013 
through November 2017, which was the time frame for collection 
and follow up of 112 paroxysmal and persistent atrial fibrillation 
patients referred for ablation. Patients eligible for this study included 
consecutive patients who had undergone their first AF ablation with 
CF catheters and the consecutive group of patients who underwent 
their first AF ablation before CF catheters were available. Exclusion 
criteria included patients who underwent ablation for arrhythmias 
other than AF or who presented for a repeat procedure.
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Abstract
Background: A major innovation in atrial fibrillation (AF) ablation has been the introduction of contact force (CF) sensing catheters.
Objective:To evaluate procedural and clinical effects of transitioning to CF-guided AF ablation.
Methods:Consecutive AF ablation patients were studiedduring the period of time of transitioning from a non-CF to CF sensing catheter. 
Procedural data recorded was total radiofrequency time, time to isolate the left pulmonary veins (LPVs), and time to isolate the right 
pulmonary veins (RPVs). Clinically, the 3 and 12-month maintenance of sinus rhythm was noted and compared by: paroxysmal vs. persistent 
AF; CT scan LA volume more or less than 150 cc; CHA2DS2VASC more or less than 2; and LVEF more or less than 55%. Safety data was 
recorded as well.
Results: Total ablation times were shorter (113 vs.146 min, p=0.011)when using the CF catheters compared to non-CF ablations. This was 
driven by a decrease in both LPV (46 vs.72 min, p<0.001) and RPV time (54 vs. 75 min, p=0.002).The use of CF catheter did not change the 
overall percentage of patients in sinus rhythm at 3 and 12-months of follow up. However, sinus rhythm was more frequent at 12 months with 
CF ablation in patients with a LA volume of more than 150 cc when compared to non-CF ablation (84.6% and 52.4%, p=0.03). There was no 
difference in outcomes with stratification by CHA2DS2VASC score or LVEF. No significant difference in complications was noted.
Conclusions:For AF ablation, the initial use of CF-sensing technology reduced procedure times with similar overall sinus rhythm 
maintenance at 3 and 12 months. CF improved 12-month outcomes in patients with an enlarged LA.
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Procedural and clinical characteristics were collected from our 
institution’s electronic health record. Of the initial 112 patients 
designated for inclusion in the study, 51 patients underwent non-CF 
ablation and 61 underwent CF ablation; 7 patients in the non-CF 
group and 10 in the CF group were excluded from analysis because 
AF ablation was not performed or the presentation was for a repeat 
ablation procedure. The data were collected and stored securely in 
a password-protected database. The study was approved by our 
institutional review board.
Catheter Ablation Procedure
All patients were referred for catheter ablation of AF and provided 
written informed consent in accordance with institutional policy. 
Antiarrhythmic medications other than amiodarone were stopped 
three days before the procedure. In brief, femoral venous access was 
obtained and a multipolar catheter was placed in the coronary sinus 
and a diagnostic intracardiac ultrasound catheter (5.5 to 10 MHz; 
AcuNav; Biosense Webster, Diamond Bar, California) was placed in 
the right atrium. Two atrial transseptal punctures were performed, 
and an ablation catheter and a circular mapping catheter (Spiral; St. 
Jude Medical) were advanced into the left atrium. Three-dimensional 
electroanatomic mapping was performed using the Velocity system 
(St. Jude Medical).
All pulmonary veins were routinely isolated, typically as a pair. 
Ablation was performed in the carina between ipsilateral veins 
if isolation could not be achieved with wide area encirclement. 
Radiofrequency ablation was delivered with a 3.5-mm open-
irrigated tip catheter or a 3.5-mm open-irrigated CF sensing catheter 
(TactiCath; St. Jude Medical, St.Paul, MN). For LA volumes 
exceeding 150 cc by cardiac CT a TactiCath 75 was used, and for a 
volume less than 150 cc a TactiCath 65 was used[9]. With the non-
CF catheter, radiofrequency was routinely delivered to lesions for 30 
to 60 secondsto achieve a decrease in impedance of at least 5 to 10 
Ohms at the ablation site. With the CF sensing catheter, ablation 
was performed with a flow of 17 cc/minute, power 20-25 watts, a 
goal of 10-40 g per lesion, and a goal of 400-500 g seconds per site 
(typically a lesion size index 4.5-5.5).  Successful PVI was defined by 
the loss of all pulmonary vein potentials (entrance block) and failure 
to capture the left atrium when pacing from sequential bipoles of the 
circular mapping catheter placed at the ostium of each pulmonary 
vein (exit block). Attempts at reinduction with burst pacing were 
performedand recorded.
The rationale for the use of CF catheters and the working 
parameters that we chose were determined by a number of published 
investigations. The first was the 2012 TOCCATA study, which was 
primarily a safety study for right and left atrial ablation using the same 
CF ablation catheter used in our study[10]. Investigators identified a 
force >100 g as a risk for perforation, which occurred in one patient. 
The EFFICAS I trial (2013) was designed to assess CF (using the 
TactiCath ablation catheter) and the ability to predict ablation gaps 
during ablation for AF[11]. The operators were blinded to the contact 
force data. The results established that a minimum CF (<10 g) and 
minimum force-time integral (FTI; <400 gs) were predictors of gaps 
in the ablation lesion set. To achieve durable lesions and to obtain 
a successful PVI, a target CF of 20 g was recommended, with an 
absolute minimum CF of 10 g and an absolute minimum FTI of 400 
gs per individual ablation lesion. The SMART AF trial (2014) was 
designed for safety and effectiveness of the SmartTouch catheter[6]. 
In this trial, when the CF was between “investigator selected working 
ranges” >80% of the time, outcomes were 4.25 times more likely 
to be successful. In 2015, the EFFICAS II, which was designed 
based on the findings in EFFICAS I with unblinded operators 
using TactiCath, found that a CF of 20g and a minimum FTI of 
400 gs reduced ablation gaps. The investigators found that fewer 
lesions were required, and lower fluoroscopy times were achieved 
with these parameters[12]. Finally, the TOCCASTAR study (2015) 
randomizedCF vs. non-CF for paroxysmal AF and looked at 1 year 
AF freedom after ablation (n=300) using TactiCath[7]. The authors 
noted that when optimal CF was used (≥90% of the lesions with a 
CF ≥10 g) outcomes were better (76% v. 58%) and fluoroscopy and 
ablation times were less. Support for the use of ablation catheters 
with CF parameters are supported by national guidelines[13].
Follow up
Patients in this practice tend to remain within the health system. 
These patients were followed up periodically with routine office 
visits at up 1, 3, 6, and 12 months and both in between visits and 
beyond 12 months if there was a reportof symptoms. Standard 
electrocardiography was performed at each follow-up visit to assess 
AF status. Mobile cardiac outpatient telemetry monitors were used 
if indicated clinically. Phone calls and emails were encouraged with 
any symptoms. At 12-month follow up, data was able to be collected 
on 30 patients in the non-CF group and 38 patients in the CF group.
Study Endpoints
The primary procedural endpoints were total radiofrequency 
time, time to complete isolation of the left pulmonary veins, time 
to complete isolation of the right pulmonary veins, and inducibility 
to AF, atrial flutter, or other arrhythmias. The primary clinical 
endpoints were the presence of AF during the first 3 and first 12 
months. Recurrence of AF was defined as 30 seconds or more of 
symptomatic or asymptomatic AF after ablation regardless of the 
pre-procedural burden or the patient’s perception of improvement 
after the procedure.
Results    
Baseline characteristics of the 95 included patients did not show 
any significant differences [Table 1]. The sample was predominantly 
men around the age of 60. Persistent AF comprised a larger propor-
tion of the sample (60%)than paroxysmal AF.
 Procedural Results
For the procedural analysis, data was complete for 86 patients. In 
each of the categories measured, there was a reduction in procedural 
time and total radiofrequency application time when a CF catheter 
was used [Table 2]. Theuse of a CF catheter significantly reduced 
the mean total ablation time by about 33 minutes (1 hour and 53 
minutes compared to 2 hours and 26 minutes, p=0.011). LPV and 
RPV times were both significantlyshorter in the CF ablation group 
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score or LVEF.
Safety Results
Overall, there was no observed increase in complications with the 
introduction of CF ablation. Pericardial effusion with or without the 
need for pericardiocentesis occurred in 3/45 = 7% of patients prior 
as well[Figure 1]. There was no difference in the ability to reinduce-
sustained atrial fibrillation, non-sustained atrial fibrillation, or other 
arrhythmias between catheter types [Table 3].
Clinical Results
We chose 2 time points to evaluate for AF recurrence: 3 months—
frequently considered the blanking period—and 12 months after 
ablation. No differencein the percentage of patients in sinus rhythm 
was detected between the CF and non-CF groups (74.5% and 
Table 1: Patient demographics and baseline data
Contact Force 
(N=51) 
Non-Contact Force 
(N=44)
p-value
Age, years  mean (STD) 60.7 (9.8) 60.3  (8.8) 0.60
Male gender, no. (%) 40 (78.4) 29 (65.9) 0.13
Paroxysmal AF, no. (%) 21 (41.2) 17 (38.6) 0.48
CHA2DS2-VASc score median (IQR) 1 (1-2) 2 (1-3) 0.24*
Anti-arrhythmic drug use, no. (%) 16 (31.4) 10 (22.7) 0.24
Anticoagulation use, no. (%) 24 (47.1) 23 (52.3) 0.38
3D LA volume, mL 162.3 (39.9) 165.6 (46.3) 0.26
Left Ventricular Ejection Fraction, % 56.6 (13.3) 55.0 (15.8) 0.29
* The nonparametric Wilcoxon rank-sum test was used to analyze CHA2DS2-VASc score, as 
median instead of mean were being compare. 
Figure 1:
Graph of total, left pulmonary vein, and right pulmonary vein 
ablation time by catheter used.
Table 2: Procedural Times. Independent two samples two-tailed t-test of left, right, and total ablation time by catheter used.
Total Ablation Time LPV Time RPV Time
Contact 
Force
Non-Contact 
Force
Contact 
Force
Non-Contact 
Force
Contact 
Force
Non-Contact 
Force
N 47 39 47 40 47 39
Mean 1:53:24 2:26:16 0:45:51 1:12:07 0:54:41 1:14:43
STD 1:03:38 0:51:11 0:24:44 0:33:55 0:25:28 0:31:33
p-value 0.011 <0.001 0.002
* All comparisons were found to be statistically significant.
68.2%, respectively; p=0.50) at the 3-month follow up period [Table 
4a]. The overall 12-month incidence of sinus rhythm was also not 
significantly different [Table 4b]; [Figure 2]). Subgroup analysis done 
at 12-month follow up showed that sinus rhythm was more frequent 
with CF compared to non-CF in patients with an LA volume greater 
than 150 cc compared (84.6% and 52.4%, respectively; p=0.03). There 
was no difference in outcomes with stratification by CHA2DS2VASC 
Table 3:
Arrhythmia Inducibitily. Independent two samples two-tailed 
t-test of left, right, and total ablation time by catheter used.
Contact Force 
(N=46)
Non-Contact Force 
(N=37)
Chi-squared P value
Non-inducible 21 13 0.094 .30
AF 6 8 .33
Non-sustained AF 2 3 .47
Typical AFL 17 9 .22
Atypical AFL 0 4 .02
* Inducibility testing was not performed on 2 patients in the Contact Force group and 3 patients in 
the non-Contact Force group. These are excluded.
** Bonferroni correction method was used to correct for multiple comparison post-hoc (adjust 
p-value=0.05/5= 0.01). No significant differences were found.
Table 4a: Clinical Outcomes. Patients in sinus rhythm after 3-months based on disease characteristics and catheter used.*
Contact Force 
(N=51)
Non-Contact Force 
(N=44)
P value
Overall patients in sinus rhythm, % (n) 78.4 (40) 68.2 (30) 0.26
Type of AF Paroxysmal 71.4 (15) 70.6 (12) 1.00
Persistent 83.3 (25) 66.7 (18) 0.22
LA volume, cc ≥ 150 76.9 (20) 61.9 (13) 0.34
< 150 80 (20) 73.9 (17) 0.74
CHA2DS2VaSc 
score
≥ 2 82.6 (19) 64.0 (16) 0.20
< 2 75.0 (21) 73.7 (14) 1.00
LVEF, % ≥ 55 78.4 (29) 80.0 (24) 1.00
< 55 78.6 (11) 42.9 (6) 0.12
* Chi-square used for overall analysis while fisher’s exact test used for subgroup comparisons as 
some cells contained numbers <10
Table 4b:
Clinical Outcomes. Patients in sinus rhythm after 12-months 
based on disease characteristics and catheter used.*
Contact Force Non-Contact Force P value
Overall patients in sinus rhythm, % (n) 74.5 (38) 68.2 (30) 0.50
Type of AF Paroxysmal 61.9 (13) 82.4 (14) 0.28
Persistent 83.3 (25) 59.3 (16) 0.08
LA volume, cc ≥ 150 84.6 (22) 52.4 (11) 0.03
< 150 64.0 (16) 82.6 (19) 0.20
CHA2DS2VaSc 
score
≥ 2 73.9 (17) 64.0 (16) 0.54
< 2 75.0 (21) 73.7 (14) 1.00
LVEF, % ≥ 55 73.0 (27) 73.3 (22) 1.00
< 55 78.6 (11) 57.1 (8) 0.42
*Chi-square used for overall analysis while fisher’s exact test used for subgroup comparisons as 
some cells contained numbers <10
to the introduction of CF catheter and in 1/52 = 2% of the patients 
who underwent ablation with a CF catheter (p=0.24). There were no 
strokes, deaths, bleeding episodes requiring transfusion, esophageal 
injuries, or phrenic nerve injuries in either group.
Discussion
The intent of this study was to quantify the impact of the 
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time, but without differentiating between LPV and RPV times[17,18].
Our study found that patients with large LA volumes (which we 
defined based on a previous investigation)undergoing AF ablation 
with a CF catheter were more likely to remain in sinus rhythm at 12 
months[9]. This difference was driven by two CF patients converting 
to sinus between the 3 and 12 month period and two non-CF patients 
who convert from sinus back to AF in the same time period.One 
long term study has shown PV reconnection in both CF and non-CF 
ablated patients owing primarily to the RPV that negated a significant 
difference in atrial arrhythmia free survival[19]. CF ablation has been 
shown to improve outcomes in patients with paroxysmal AF in large 
studies[20-22] and subsequent research on persistent AF has shown a 
benefit as well[23]. Patients with exclusively persistent AF and large 
LA enlargement, however,have been shown not to have an increase 
in sinus rhythm at 12 months[24]. Our analysis did not compare these 
two covariates directly, and it is possible that the advantage seen in 
our study was due to patients with large LA volumes and specifically 
paroxysmal AF.
Our complication rates were low in both arms, and similar to those 
of other studies involving CF ablations[23,24]. Larger studies with 
longer follow up have seen a reduction in complications with CF 
ablation so it is possible that we lacked significant enough power to 
detect a difference in complication rate[24].
This study has several limitations. First, the sample size is small. 
Despite initially selecting 112 charts, only 68 patients who met 
inclusion criteria completed their 12-month follow up. The patients 
lost to follow up appear in proportion between both the CF and non-
CF group, but nevertheless this may result in unintended selection 
bias. Second, despite outpatient telemetry monitoring and regular 
electrocardiography it remains possible that patients had recurrences 
that asymptomatic and unrecorded. Third, subgroup analysis was not 
performed on procedural outcomes. Certain patient characteristics 
may have impacted procedural times. Finally, mean times to perform 
each AF ablation were reported. Changes in procedural time may 
have occurred towards the end of the CF group as the operator 
became more familiar with technology.
Conclusions
For atrial fibrillation ablation, introduction of CF-sensing 
technology reduced procedure times with similar overall sinus 
rhythm maintenance at 12 months. Notably, CF improved 12-month 
outcomes in patients with an enlarged left atrium.
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